MX2017013248A - Compuesto del inhibidor fgfr4 cristalino y usos del mismo. - Google Patents

Compuesto del inhibidor fgfr4 cristalino y usos del mismo.

Info

Publication number
MX2017013248A
MX2017013248A MX2017013248A MX2017013248A MX2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A MX 2017013248 A MX2017013248 A MX 2017013248A
Authority
MX
Mexico
Prior art keywords
crystalline
inhibitor compound
fgfr4 inhibitor
salt form
fgfr4
Prior art date
Application number
MX2017013248A
Other languages
English (en)
Inventor
Sanders Kristen
Yoshida Kenshi
Chanda Arani
Moniz George
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017013248A publication Critical patent/MX2017013248A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se una serie de formas cristalinas de N-(2-((6-(3-(2,6-dicloro-3,5 -dimetoxifenil)-1-metilureido) pirimidin-4-il)amino)-5-(4-etilpipe razin-1-il)fenil)acrilamida. í‰stas incluyen una forma cristalina de base libre, una forma cristalina en sal monoclorhidrata, una forma cristalina de sal diclorhidrata, y una forma cristalina de sal etansulfonato. Tambión se proporcionan los métodos para elaborar y utilizar los compuestos cristalinos.
MX2017013248A 2015-04-14 2016-04-13 Compuesto del inhibidor fgfr4 cristalino y usos del mismo. MX2017013248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147313P 2015-04-14 2015-04-14
PCT/US2016/027334 WO2016168331A1 (en) 2015-04-14 2016-04-13 Crystalline fgfr4 inhibitor compound and uses thereof

Publications (1)

Publication Number Publication Date
MX2017013248A true MX2017013248A (es) 2018-07-06

Family

ID=55806857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013248A MX2017013248A (es) 2015-04-14 2016-04-13 Compuesto del inhibidor fgfr4 cristalino y usos del mismo.

Country Status (13)

Country Link
US (2) US10562888B2 (es)
EP (1) EP3283465B1 (es)
JP (3) JP6431622B2 (es)
KR (1) KR102548229B1 (es)
CN (1) CN107660200B (es)
AU (2) AU2016248056B2 (es)
CA (1) CA2982562C (es)
ES (1) ES2864712T3 (es)
IL (1) IL254974B (es)
MX (1) MX2017013248A (es)
RU (1) RU2763328C2 (es)
SG (2) SG11201708472WA (es)
WO (1) WO2016168331A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562888B2 (en) 2015-04-14 2020-02-18 Eisai R&D Management Co., Ltd. Crystalline FGFR4 inhibitor compound and uses thereof
WO2017196854A1 (en) 2016-05-10 2017-11-16 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CA3034875A1 (en) * 2016-08-23 2018-03-01 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
JP7063899B2 (ja) * 2016-11-17 2022-05-09 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ４阻害剤、その製造方法及び使用
CN109422760B (zh) * 2017-09-01 2022-05-27 南京圣和药物研发有限公司 Fgfr4抑制剂及其应用
US11833119B2 (en) 2018-01-10 2023-12-05 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
WO2021231928A1 (en) * 2020-05-15 2021-11-18 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an fgfr4 inhibitor
JP2023533903A (ja) 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69515898T2 (de) * 1994-11-14 2000-08-17 Warner Lambert Co 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG
WO1999061444A2 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
CN1860118A (zh) 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
JP5153645B2 (ja) 2005-12-21 2013-02-27 ノバルティス アーゲー Ｆｇｆ阻害剤であるピリミジニルアリールウレア誘導体
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
US20090062320A1 (en) 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20140051662A1 (en) 2011-04-08 2014-02-20 Ab Science Treatment of multiple myeloma with masitinib
CN102816162B (zh) 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
EP2804630B1 (en) 2012-01-18 2017-10-18 F. Hoffmann-La Roche AG Methods of using fgf19 modulators
JP5343177B1 (ja) 2012-02-28 2013-11-13 アステラス製薬株式会社 含窒素芳香族へテロ環化合物
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
EP2968337B1 (en) 2013-03-15 2021-07-21 Celgene CAR LLC Heteroaryl compounds and uses thereof
JP2016523973A (ja) 2013-07-09 2016-08-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 疾患の処置のためのキナーゼ阻害物質
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
CN105899490B (zh) * 2013-10-18 2019-07-23 卫材R&D管理有限公司 嘧啶fgfr4抑制剂
PL3395814T3 (pl) 2013-10-25 2022-08-22 Blueprint Medicines Corporation Inhibitory receptora czynników wzrostu fibroblastów
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10562888B2 (en) * 2015-04-14 2020-02-18 Eisai R&D Management Co., Ltd. Crystalline FGFR4 inhibitor compound and uses thereof
EP3444250A4 (en) 2016-05-20 2019-09-25 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. FGFR4 INHIBITOR, PROCESS FOR PREPARATION AND CORRESPONDING APPLICATIONS
TWI669300B (zh) 2016-05-20 2019-08-21 浙江海正藥業股份有限公司 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途

Also Published As

Publication number Publication date
RU2017139246A (ru) 2019-05-14
CA2982562C (en) 2023-06-13
AU2016248056A1 (en) 2017-11-02
CA2982562A1 (en) 2016-10-20
KR20180003559A (ko) 2018-01-09
US10562888B2 (en) 2020-02-18
AU2016248056B2 (en) 2020-07-23
US20180093972A1 (en) 2018-04-05
ES2864712T3 (es) 2021-10-14
WO2016168331A1 (en) 2016-10-20
BR112017022243A2 (pt) 2018-07-10
IL254974B (en) 2021-06-30
CN107660200B (zh) 2022-01-11
US11498916B2 (en) 2022-11-15
EP3283465A1 (en) 2018-02-21
US20200317645A1 (en) 2020-10-08
JP6431622B2 (ja) 2018-11-28
RU2763328C2 (ru) 2021-12-28
JP2021050231A (ja) 2021-04-01
SG11201708472WA (en) 2017-11-29
RU2017139246A3 (es) 2019-10-22
SG10201810057UA (en) 2018-12-28
IL254974A0 (en) 2017-12-31
JP2018188465A (ja) 2018-11-29
KR102548229B1 (ko) 2023-06-27
EP3283465B1 (en) 2021-01-06
AU2020257131A1 (en) 2020-11-19
JP2018511635A (ja) 2018-04-26
CN107660200A (zh) 2018-02-02

Similar Documents

Publication Publication Date Title
MX2017013248A (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
IL276948B (en) n-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
NZ739893A (en) Fused pyrimidine compound or salt thereof
RS54653B1 (en) 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
NZ719688A (en) Pesticidal compositions and related methods
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
ZA201907272B (en) N-(4-pyridyl)nicotinamide compound or salt thereof
UY37121A (es) Compuestos de N-(2-(fenil) piridina-4-il)-5-morfolinopiridina-3-sulfonamida como inhibidores de la actividad PL3-quinasa
TW201613888A (en) Crystalline forms of an NK-1 antagonist
PH12018501898A1 (en) Herbicidal compositions containing 2-chloro-3-(methylsulfanyl)-n-(1-methyl-1h-tetrazole-5-yl)-4-(trifluoromethyl)benzamide
HUE063662T2 (hu) Helyettesített piridiniloxibenzol, sói és gyomirtó hatóanyagként való alkalmazása
MX2021010016A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
UA114081U (uk) 5-(2-(4-(диметиламіно)бензиліден)гідразиніл)-4-феніл-4h-1,2,4-триазол-3-тіолу гідрохлорид, що стимулює ріст пшениці озимої
UA94667U (uk) Заміщені [2-(3-r-1h-[1,2,4]триазол-5-іл)феніл]аміни, що проявляють гіпоглікемічну активність